WallStSmart

ICL Israel Chemicals Ltd (ICL)vsNutrien Ltd (NTR)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Nutrien Ltd generates 255% more annual revenue ($27.36B vs $7.71B). NTR leads profitability with a 8.0% profit margin vs 4.0%. NTR appears more attractively valued with a PEG of 1.98. ICL earns a higher WallStSmart Score of 62/100 (C+).

ICL

Buy

62

out of 100

Grade: C+

Growth: 6.7Profit: 5.0Value: 4.7Quality: 6.0
Piotroski: 2/9Altman Z: 2.13

NTR

Buy

53

out of 100

Grade: C-

Growth: 2.7Profit: 6.0Value: 4.7Quality: 5.8
Piotroski: 6/9Altman Z: 1.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICLUndervalued (+0.2%)

Margin of Safety

+0.2%

Fair Value

$5.76

Current Price

$4.59

$1.17 discount

UndervaluedFair: $5.76Overvalued
NTRSignificantly Overvalued (-28.9%)

Margin of Safety

-28.9%

Fair Value

$56.69

Current Price

$71.22

$14.53 premium

UndervaluedFair: $56.69Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICL3 strengths · Avg: 9.3/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

EPS GrowthGrowth
51.6%10/10

Earnings expanding 51.6% YoY

Revenue GrowthGrowth
16.5%8/10

16.5% revenue growth

NTR2 strengths · Avg: 9.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

ICL4 concerns · Avg: 2.8/10
Return on EquityProfitability
4.3%3/10

ROE of 4.3% — below average capital efficiency

Profit MarginProfitability
4.0%3/10

4.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

PEG RatioValuation
9.442/10

Expensive relative to growth rate

NTR4 concerns · Avg: 3.5/10
PEG RatioValuation
1.984/10

Expensive relative to growth rate

Revenue GrowthGrowth
1.2%4/10

1.2% revenue growth

Altman Z-ScoreHealth
1.734/10

Distress zone — elevated risk

EPS GrowthGrowth
-37.6%2/10

Earnings declined 37.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : ICL

The strongest argument for ICL centers on Price/Book, EPS Growth, Revenue Growth. Revenue growth of 16.5% demonstrates continued momentum.

Bull Case : NTR

The strongest argument for NTR centers on Price/Book, P/E Ratio.

Bear Case : ICL

The primary concerns for ICL are Return on Equity, Profit Margin, Piotroski F-Score. Thin 4.0% margins leave little buffer for downturns.

Bear Case : NTR

The primary concerns for NTR are PEG Ratio, Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

ICL profiles as a growth stock while NTR is a value play — different risk/reward profiles.

NTR carries more volatility with a beta of 1.13 — expect wider price swings.

ICL is growing revenue faster at 16.5% — sustainability is the question.

ICL generates stronger free cash flow (93M), providing more financial flexibility.

Bottom Line

ICL scores higher overall (62/100 vs 53/100) and 16.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ICL Israel Chemicals Ltd

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

ICL Group Ltd, is a company specialized in minerals and chemical products worldwide. The company is headquartered in Tel Aviv, Israel.

Visit Website →

Nutrien Ltd

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Nutrien Ltd. provides inputs, services and solutions for crops. The company is headquartered in Saskatoon, Canada.

Visit Website →

Want to dig deeper into these stocks?